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Available online at www.sciencedirect.comHIV-1 reverse transcriptase (RT) contributes to the development
of resistance to all anti-AIDS drugs by introducing mutations into
the viral genome. At the molecular level, mutations in RT result in
resistance to RT inhibitors. Eight nucleoside/nucleotide analogs
(NRTIs) and five non-nucleoside inhibitors (NNRTIs) are
approved HIV-1 drugs. Structures of RT have been determined in
complexes with substrates and/or inhibitors, and the structures
have illuminated different conformational and functional states of
the enzyme. Understanding the molecular mechanisms of
resistance to NRTIs and NNRTIs, and their complex
relationships, may help in designing new drugs that are
periodically required to overcome existing as well as emerging
trends of drug resistance.
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Background
AIDS started spreading silently in the 1970s, and came
into the limelight in the early 1980s as a mysterious
pandemic that was one of the most serious public health
threats in history. In the 1980s, clinical and scientific
research communities were confronted with unexpected
overwhelming challenges to understand the cause and
mystery behind AIDS, and to find prevention and treat-
ment options. Detection of reverse transcription activity
in cultures of lymph node cells taken from AIDS patients
in the early 1980s [1,2] revealed that AIDS is caused by a
retrovirus that was subsequently named the human
immunodeficiency virus (HIV).
Reverse transcription is a key step in the life cycle of
retroviruses, and the process is responsible for synthesis of
double-stranded (ds) DNA from a viral single-stranded
(ss) RNA genome. A viral DNA polymerase or reverse
transcriptase (RT) enzyme is responsible for synthesis of
DNA complementary to an RNA or DNA template. Notwww.sciencedirect.com surprisingly, the reverse transcription/DNA polymeriz-
ation step in HIV replication was immediately considered
as a prime drug target, and the nucleoside analog AZT
(zidovudine, ZDV) [3,4] was approved as the first anti-
AIDS drug. Clinical use of AZT revealed that treatment
of HIV infection with a single drug was not effective in
keeping the viral load down for a prolonged period. Also,
it was realized that HIV could not be cleared from an
infected individual, and drug-resistant viruses emerged
with loss of sensitivity to AZT.
Even today, challenges like discovery of an effective
AIDS vaccine, complete cure from HIV infection, and
effective ways to overcome drug resistance remain as
open questions. However, sincere scientific research com-
mitments initiated and supported by public and private
initiatives have led to the development of drugs and
treatment strategies that help HIV infected individuals
lead a near normal lifespan if the patient complies with
treatments to maintain viral load at or near undetected
level. HIV-1 is the predominant virus that spreads AIDS.
So far 26 individual anti-AIDS drugs have been approved,
of which 13 target RT. The remaining drugs target several
key steps in the viral lifecycle, namely: first, the enzyme
protease that is responsible for cleaving the viral poly-
protein precursors into functional entities and for matu-
ration of virus particles; second, the enzyme integrase that
integrates the viral dsDNA to the host cell chromosome;
and third, viral entry/fusion.
HIV-1 exhibits high genetic variability, and thereby,
HIV-1 develops resistance to existing drugs and escapes
host immune responses elicited by AIDS vaccine candi-
dates. HIV-1 enters a host cell by binding the CD4
receptor on the surface of immune cells and a co-receptor,
either CCR5 or CXCR4. Entry and fusion of an HIV-1
particle releases its two copies of the viral ssRNA genome,
about fifty copies of RT, and other viral entities into the
cytoplasm. RT copies the viral genome into a dsDNA that
is subsequently transported into the nucleus of the
infected cell and integrated into the host cell chromo-
some by another viral enzyme, integrase. Recently
approved integrase inhibitors (raltegravir and elvitegravir)
bind the active site of HIV-1 integrase in a pre-integration
complex [5,6] and block the viral DNA integration into
host cell chromosomes.
Usually, three or four drugs are combined in a treatment
regimen, commonly referred to as highly active antire-
troviral therapy (HAART). Some of the widely used
treatment regimens include: first, two nucleoside RT
inhibitors (NRTIs) + one non-nucleoside RT inhibitorCurrent Opinion in Virology 2013, 3:111–118
112 Virus structure and function(NNRTI) or protease inhibitor (PI); and second, combi-
nations of an integrase or entry inhibitor with RT inhibi-
tors and PIs. Selecting the right treatment strategies and
combinations remain challenging due to factors such as:
first, limitations in availability of drugs at different geo-
graphic locations and socioeconomic conditions; second,
compatibilities among individual drugs and adherence;
third, side effects from long-term use of drugs; fourth,
existence and emergence of drug resistance; and fifth,
different responses by treatment-naive or treatment-
experienced individuals, among others. However, three
decades of extensive research on various aspects of HIV-1
and related viruses have brought success in effectively
managing HIV-1 infection, and the scientific knowledge
garnered has in many ways blazed the trail for finding
treatment solutions for several challenging chronic dis-
eases and emerging drug-resistance problems.
The RT enzyme is a critical molecular machine of HIV-1
that is targeted by the largest number of anti-AIDS drugs.
At the same time, RT is responsible for developing resist-
ance to all anti-AIDS drugs: first, directly to RT inhibitors
at the molecular level and/or second, indirectly as a primary
source for introducing genetic variations. In this two-part
review, we discuss the critical roles of RT in developing
drug resistance, a structural perspective on molecular
mechanisms of RT inhibition and drug resistance, and
possible molecular bases for synergistic benefits of several
RT drug combinations used to combat drug resistance.
RT in generating HIV-1 quasispecies —
evolution of drug resistance
Drug resistance evolution is a primary phenomenon that
helps a pathogen survive and replicate even under harsh
drug pressure. An HIV-1 infected individual harbors a
pool of HIV-1 variants generated initially mostly from one
(a ‘founder’) that had transmitted the infection [7]. In
general, a virus yields a pool of ‘quasispecies’ [8] by
undergoing genetic variations that arise from errors made
by HIV-1 while copying its genetic information combined
with a very high rate of HIV-1 turnover [9]. RT copies the
10 000 nucleotide RNA HIV-1 genome [10,11] into
dsDNA via RNA-dependent and DNA-dependent
DNA polymerization, a process requiring 20 000
nucleotide incorporation steps. RT is an error-prone
enzyme that introduces approximately one misincorpora-
tion per 104 nucleotide incorporations at the enzyme
level. Apparently, the rate of error is lower in viral
replication than that expected based on RT misincorpora-
tion data. The in vivo mutation rate in viral replication is
105, a order of magnitude lower than that observed
with RT [12]. Apart from RT, the host RNA polymerase
may also introduce mutations while transcribing the viral
DNA to mRNA copies that are first, translated into viral
polyproteins and second, processed into viral ssRNA
copies. The errors are random, resulting in random
sequence changes in the progeny viruses and translatedCurrent Opinion in Virology 2013, 3:111–118 viral proteins. Many, if not most, of the mutations may be
deleterious for the structural assembly or the functions of
viral proteins, and therefore the virus cannot afford those
mutations. Interestingly, HIV-1 can retain its activity
despite carrying several mutations, and each of these
mutant strains can replicate and generate new variants.
Each replication cycle expands heterogeneity in the pool
of viruses in an HIV-1 infected individual.
The wild-type variants are well adapted to the natural
host environment and replicate as the predominant
strains whereas various quasispecies replicate less effi-
ciently. However, the replication dynamics changes
under drug selection pressure. A typical drug is primarily
designed to hit the wild-type virus hard. The mutants that
are least inhibited by the drugs emerge as the predomi-
nant variants. At times, such a drug-resistant variant may
be less fit on its replication or transmission capability;
however, some of these variants may gain fitness either by
accruing compensatory mutations or by adding resistance
mutations to an existing variant containing the compen-
satory mutation background.
Structures and conformations of RT
RT is a heterodimer consisting of two polypeptide chains
p66 (66 kDa; 560 amino acid residues) and p51 (51 kDa;
440 amino acid residues). Large precursor polyproteins
translated from the HIV-1 pol gene are cleaved by HIV-1
protease to produce the p66 subunit. The p66 chain
contains an N-terminal polymerase domain and a C-
terminal RNase H domain. A likely scenario appears to
be that two p66 chains dimerize, and HIV-1 protease
cleaves the RNase H moiety of one chain to produce a
stable p66/p51 heterodimeric RT. The structural archi-
tecture of RT (Figure 1a) has been known for two
decades [13,14]. The p66 chain contains both the poly-
merase and RNase H active sites. The polymerase
domain of RT (Figure 1b) resembles the shape of a ‘right
hand’ with fingers, palm, thumb and connection subdo-
mains; the connection subdomain links the polymerase
domain to the RNase H domain. The p51 chain also
contains the fingers, palm, thumb, and connection sub-
domains; however, the subdomains have different spatial
arrangements in p51 than in p66. The subdomains in p51
are assembled into a relatively rigid structure that pro-
vides structural support to p66. The subdomains in p66
are flexible, and can be spatially rearranged to different
conformational states necessary to carry out the functions
of RT. Structures representing five conformational/
functional states of RT have been determined
(Figure 2). Some of the major conformational rearrange-
ments revealed by RT structures are: first, the thumb lifts
up to bind nucleic acid; second, the fingers fold down to
hold a dNTP substrate in the presence of a nucleic acid;
third, NNRTI-binding leads to thumb hyperextension
even if RT is not bound to a nucleic acid; and fourth,
nucleic acid at the polymerase active site is repositionedwww.sciencedirect.com
HIV-1 RT and antiviral resistance Das and Arnold 113
Figure 1
Fingers
Template
Primer
dNTP
(a) (b)
Thumb
Palm
Connection RNase H Primer
Template
Fingers
NRTI-TP
NNRTI
Pol site 115
210
215
219
108106
190
179
236
188
181
138
101
100
184
67 65
74151
70
41
103
3′-OH
PalmRNase H
active site
p51
p66
Current Opinion in Virology
HIV-1 RT structure and sites for common drug-resistance mutations. (a) A ribbon representation of the structure of HIV-1 RT-DNA-dNTP complex.
(b) Sites of commonly observed NRTI-resistance mutations (magenta) and NNRTI-resistance mutations (cyan) in the fingers and palm subdomains of
HIV-1 RT.upon binding of an NNRTI to RT-DNA complex. These
structural rearrangements of RT result from inter-sub-
domain hinge movements and local structural rearrange-
ments while the overall structural folds of individual
subdomains remain almost invariant.
The sites of mutations that confer resistance to either
NRTI or NNRTI drugs are primarily located in the
polymerase domain (Figure 1b). Routine RT sequen-
cing from clinical isolates were limited to the polymer-
ase domain only where primary NRTI-resistance and
NNRTI-resistance mutations occur. Relatively recent
sequencing of the complete RT from clinical isolates
has shown that mutations in the remote connection
subdomain and RNase H domain enhance resistance
to both classes of RT drugs [15,16] by indirect mech-
anisms that are not well understood. This review
focuses on the NRTI and NNRTI drugs, and the
primary resistance mutations that are confined to the
polymerase domain.
Nucleoside analog (NRTI) drugs
Nucleotide misincorporations by RT contribute to gen-
erating mutant HIV-1 proteins including mutant RTs,
and mutant RTs can develop resistance to RT inhibitors.
Drugs targeting HIV-1 RT are either NRTIs or NNRTIs.
An NRTI (Figure 3a) is converted to a dNTP analog by a
phosphorylation cascade performed by cellular kinases,
and then RT catalytically incorporates the drug as an
NRTI monophosphate (or a nucleotide analog) at the 30-
end of the growing viral DNA primer; pyrophosphate is
released as the reaction byproduct. Nucleoside phospho-
nate analogs like tenofovir (a ‘nucleotide analog’) requirewww.sciencedirect.com addition of b-phosphates and g-phosphates whereas the
other NRTIs are elaborated with a-phosphates, b-phos-
phates, and g-phosphates. Efficient intracellular phos-
phorylation of NRTI to NRTI-triphosphate (TP) is an
essential requirement for the efficacy of an NRTI drug.
Upon incorporation, an NRTI inhibits the elongation of
DNA primer because NRTIs lack a 30-OH group and/or
contain a modified sugar moiety that prevents addition of
the next nucleotide. An NRTI-TP does not block the
activity of an RT molecule; however, certain RT
mutations cause NRTI resistance by discriminating an
NRTI-TP from the analogous dNTP substrate. NRTI-
resistance mutations primarily appear along the dNTP-
binding track extending from the b3–b4 fingers loop
region to YMDD residue M184 (Figure 1b). Also, RT
has the ability to remove certain NRTIs from the DNA
primer (‘unblocking’) by reversing the direction of its
catalytic reaction of polymerization [17,18]. The molecu-
lar mechanisms of individual resistance mutations are
unique and relationships among the mutations are com-
plex. Biochemical and structural studies have unraveled
some of the unique resistance mechanisms and their
relationships that are discussed in Part 2 of this review
article.
Non-nucleoside RT inhibitors (NNRTIs)
Unlike NRTIs that do not directly inhibit RT, an
NNRTI drug binds to a hydrophobic pocket in the palm
subdomain adjacent to the base of the thumb subdomain
(Figure 2d) and allosterically inhibits DNA polymeriz-
ation. The NNRTI pocket permits the design of highly
specific inhibitors having low toxicities and minimal side
effects. In fact, the NNRTIs are HIV-1 specific and evenCurrent Opinion in Virology 2013, 3:111–118
114 Virus structure and function
Figure 2
Polymerase
active site
Palm
DNA
dNTP
dNTP
Nevirapine
dTTP
DNA
NNRTI
NNRTI
Nevirapine
Primer
Template
Thumb
(a)
(b)
(c)
(d)
(e)
Fingers
RT (pol domain)
RT/DNA/NNRTIRT/DNA/dNTP
RT/DNA
RT/NNRTI
Current Opinion in Virology
Five structurally characterized conformational states of HIV-1 RT; only the polymerase domain (fingers (blue), palm (red), and thumb (green)) of RT is
shown. (a) Thumb is positioned near the fingers in a closed conformation that occupies the nucleic acid binding cleft in apo HIV-1 RT structures [29].
(b) Upon binding of a nucleic acid substrate, the thumb is lifted up and acts as a clamp to hold the nucleic acid [14]; the primer 30-end is positioned at
the polymerase active site (D110, D185, and D186) that is highlighted by a dotted ellipse. (c) Binding of a dNTP to RT-DNA complex results in closing of
the fingers to bind a dNTP in a catalytically competent state [30]. (d) Binding of an NNRTI to RT causes several conformational changes; thumb
subdomain is lifted to a hyper-extended position and the nucleic acid-binding cleft is open even in absence of a nucleic acid [13]. (e) Binding of an
NNRTI to RT-DNA complex resulted in reduction of DNA interactions with the polymerase domain of RT, and repositioning of the primer 30-end away
from the polymerase active site [31]; the structural study revealed no ordered dNTP binding to RT-DNA-NNRTI complex.do not effectively inhibit HIV-2 RT. The NNRTI pocket
is not required to be highly conserved for carrying out
the enzymatic activity unlike the conserved active
site or dNTP-binding site of RT. Therefore, HIV-1
has a relatively lower genetic barrier for developingCurrent Opinion in Virology 2013, 3:111–118 NNRTI-resistance mutations than for NRTI-resistance
mutations. Primary NNRTI-resistance mutations appear
in and around the NNRTI pocket, that is, most of the
pocket residues can mutate to confer NNRTI resistance.
There are five NNRTI drugs approved for treating HIV-1www.sciencedirect.com
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The chemical structures of anti-AIDS drugs that target HIV-1 RT. (a) The clinically approved NRTIs are: first, AZT (zidovudine, ZDV, azidothymidine,
Retrovir1) has a 30-azido group substituted for the 30-OH of dTTP; second, ddC (dideoxycytidine, zalcitabine, Hivid1); third, ddI (didanosine, Videx1),
and fourth, d4T (stavudine, Zerit1) lack 30-OH groups; fifth, ABC (abacavir, Ziagen1) has a cyclopentene ring; sixth, 3TC (lamivudine, Epivir1) has an
altered b-L-pseudo-ribose ring; seventh, FTC (emtricitabine, Emtriva1), and eigth, TFV (tenofovir) is a nucleotide analog that has an acyclic
methoxypropyl moiety substituted for the deoxyribose ring of dATP; tenofovir is formulated as tenofovir disoproxil fumarate (TDF, PMPA, Viread1). (b)
Chemical structures of the five NNRTI drugs approved for treating HIV-1 infections. First, nevirapine (NEV, Viramune1); second, delavirdine (DLV,
Rescriptor1); third, efavirenz (EFV, Sustiva1); fourth, etravirine (ETR, Intelence1); and fifth, rilpivirine (RPV, Edurant1).infections — nevirapine (NEV, Viramune1), efavirenz
(EFV, Sustiva1), delavirdine (DLV, Rescriptor1), etra-
virine (ETR, Intelence1), and rilpivirine (RPV, Edur-
ant1) (Figure 3b). An NNRTI is generally used inwww.sciencedirect.com combination with NRTIs because the two classes of
RT drugs have non-overlapping inhibition mechanisms
and resistance mutation sites, and NNRTI-resistance
mutations can emerge relatively quickly.Current Opinion in Virology 2013, 3:111–118
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Wiggling and jiggling of an NNRTI to retain potency against drug-resistance mutations. (a) Chemical structure of rilpivirine; the five torsionally flexible
bonds define the conformational freedom of the NNRTI. (b) Thermal ellipsoid representation of rilpivirine drawn using the anisotropic B-factors of
individual atoms from a 1.5 A˚ resolution structure of RT-rilpivirine complex (PDB ID 4G1Q) [25]. The interacting side chains and water molecules (red)
are displayed. (c and d) Comparison of the binding modes of rilpivirine to wild-type RT (gray) vs. L100I + K103N mutant RT (cyan) revealed how
the drug jiggles and wiggles, respectively, to evade the effects of drug-resistance mutations [23]; the mutations modify the side chains from yellow
to orange.The first-generation NNRTI drug nevirapine invokes
resistance mutations even after a single dose that is
frequently given to pregnant mothers to prevent
mother-to-child transmission of HIV-1. An effective
NNRTI should overcome the impacts of common
drug-resistance mutations — a challenge emerged with
the discovery of first-generation NNRTIs in early 1990s.
The initial structure of the RT-nevirapine complex [13]
revealed the hydrophobic NNRTI-binding pocket which
is 10 A˚ away from the polymerase active site. The first-
generation NNRTIs nevirapine, TIBO, and a-APA were
found to assume a common ‘butterfly-like’ binding mode
despite their broad chemical diversity [19]. These
NNRTIs could be optimized to nanomolar inhibitors
of wild-type virus/enzyme; however, they drastically lose
their potency against a single common NNRTI-resist-
ance mutation such as K103N or Y181C. The diarylpyr-
imidine (DAPY) NNRTI drugs ETR and RPV wereCurrent Opinion in Virology 2013, 3:111–118 developed out of a structure-based multidisciplinary
approach [20–22], and these drugs inhibited HIV-1 carry-
ing common NNRTI-resistance mutations. The DAPY
NNRTIs exhibit conformational flexibility that helps the
drugs reorient (‘wiggle’) and reposition (‘jiggle’) to retain
binding efficacy to RT even when pocket mutations
emerge [20] (Figure 4a,b). Further, the structures of
rilpivirine in complexes with wild-type and two double
mutant (K103N + Y181C and K103N + L100I) RTs
demonstrated how the NNRTI RPV wiggles and jiggles
in the pocket to retain its binding affinity [23]
(Figure 4c,d). The predominant inhibitor–protein inter-
actions associated with NNRTI binding are: first, hydro-
phobic sandwiches; second, a characteristic hydrogen
bond with the K101 main-chain carbonyl oxygen; and
third, water-mediated hydrogen bonds. It is important
that an NNRTI retains these interactions with RT while
it wiggles and jiggles in NNRTI pocket. The most recentwww.sciencedirect.com
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and jiggle by which it retains all of the above interactions
including the key hydrogen-bonding interaction with the
K101 main-chain carbonyl when it binds wild-type RT or
the two double mutants [23]. A recent study shows that
an NNRTI designed to have additional hydrogen
bonds with RT while maintaining its flexibility has
improved resilience against resistance mutations [24].
The cyanovinyl group of rilpivirine can swivel to main-
tain interactions with RT (Figure 4a); addition of the
cyanovinyl group, that is, chemical modification from
TMC120 ! rilpivirine, enhanced the inhibition potency
by 3-fold. A recent collaborative study combining 2D
infrared (IR) spectroscopy, high-resolution (1.51 A˚) crys-
tal structure, and molecular dynamics simulation of ril-
pivirine bound to RT demonstrated the involvement of
the cyanovinyl group with an invariant water-mediated
interaction that may be a critical feature for future
NNRTI design considerations (Figure 4b) [25]. Rilpi-
virine possesses highly favorable pharmacokinetics, that
in combination with its high resilience to drug-resistance
mutations demonstrate clinical efficacy even at relatively
low doses of 25 mg/day (efavirenz is usually administered
at 600 mg/day). This ideal pharmacokinetic character-
istic of RPV may correlate with its property to form
ordered nanoparticles with diameter 100 nM, whereas
several related compounds including ETV which did not
exhibit as favorable pharmacokinetics, were found to
form disordered aggregates rather than uniform nanopar-
ticles [26]. However, new drug-resistance patterns
emerge from long-term use and combination therapies,
discussed later. Understanding the molecular mechan-
ism of NNRTI inhibition and resistance caused by
different mutations may help with designing both future
drugs and optimal drug combinations.
Drug combinations for suppressing antiviral
resistance
Fusion of a virus into a host cell starts the infection with
the release of two copies of viral RNA and about fifty
copies of RT into cytoplasm. In theory only a single RT
molecule could be adequate to carry out the entire reverse
transcription process. A complex set of factors determine
the clinical efficacy of drugs targeting HIV-1 RT [27]. It
is unlikely that an NNRTI at its IC50 cellular concen-
tration would inhibit all RT molecules for complete
blockage of HIV-1 replication; the effective concen-
tration of an NNRTI for 100% inhibition is significantly
higher than its IC50 concentration [28], and the effective
concentration can be unattainably high if drug-resistant
RTs are present. The effective inhibitory concentration
for an NRTI in a cell also depends upon the efficiency of
the cellular phosphorylation of the NRTI. NRTI-blocked
primers are generally repaired by removing the NRTI.
These are among several factors that help virus replicate
even when attempts are made to block viral replication by
multiple drugs.www.sciencedirect.com The next part (Part 2) discusses structural and biochemical
understanding of mechanisms of resistance to HIV-1 drugs
that RT develops by acquiring various mutations.
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